FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076229213> ?p ?o ?g. }

• W2076229213 endingPage "855" @default.
• W2076229213 startingPage "848" @default.
• W2076229213 abstract "BackgroundEarly markers that predict immunologic long-term nonprogression in infants with perinatally acquired HIV infection might assist in subsequent antiretroviral treatment decisions.ObjectivesWe sought to identify early markers of immunologic long-term HIV disease nonprogression.MethodsWe analyzed immunologic and virologic characteristics at 1 and 2 months of age in HIV-infected children who were enrolled in the Women and Infants Transmission Study and born before 1995, comparing immunologic long-term nonprogressors (ILTNPs; n = 10) with non-ILTNPs (n = 127). ILTNPs were children who survived to 8 years or older with CD4 percentages of 25% or greater and counts of 500 cells/mm3 or more without receiving highly active antiretroviral therapy. Non-ILTNPs were defined as all other HIV-infected children. Receiver operating characteristic curve analysis was used to assess combined sensitivity and specificity for each of these characteristics and to determine potential threshold values to discriminate between ILTNPs and non-ILTNPs.ResultsCharacteristics in the first 2 months of life associated with ILTNP status in univariate analysis included higher CD4 percentages, lower CD8+ percentages, lower CD8+HLA-DR+ percentages, and lower HIV-1 RNA PCR values. In receiver operating characteristic analysis CD8+HLA-DR+ percentage had the best combined sensitivity and specificity for discriminating between ILTNPs and non-ILTNPs. CD8+HLA-DR+ percentages of 5% or less predicted ILTNP status with 80% sensitivity and 80% specificity. In multivariate analysis CD8+HLA-DR+ percentage of 5% or less remained a significant predictor of ILTNP status after adjusting for CD3+CD4+ percentage and HIV-1 RNA PCR value (odds ratio, 15.4; 95% CI, 1.9-124.7).ConclusionCD8+ HLA-DR+ T-lymphocyte percentage of less than 5% at 1 to 2 months of age might be predictive for ILTNP status but should not be used at this time to make treatment-deferral decisions. Immune activation in HIV-infected infants might herald more disease progression. Further study of the use of this subpopulation in early infancy to predict ILTNP status is warranted. Early markers that predict immunologic long-term nonprogression in infants with perinatally acquired HIV infection might assist in subsequent antiretroviral treatment decisions. We sought to identify early markers of immunologic long-term HIV disease nonprogression. We analyzed immunologic and virologic characteristics at 1 and 2 months of age in HIV-infected children who were enrolled in the Women and Infants Transmission Study and born before 1995, comparing immunologic long-term nonprogressors (ILTNPs; n = 10) with non-ILTNPs (n = 127). ILTNPs were children who survived to 8 years or older with CD4 percentages of 25% or greater and counts of 500 cells/mm3 or more without receiving highly active antiretroviral therapy. Non-ILTNPs were defined as all other HIV-infected children. Receiver operating characteristic curve analysis was used to assess combined sensitivity and specificity for each of these characteristics and to determine potential threshold values to discriminate between ILTNPs and non-ILTNPs. Characteristics in the first 2 months of life associated with ILTNP status in univariate analysis included higher CD4 percentages, lower CD8+ percentages, lower CD8+HLA-DR+ percentages, and lower HIV-1 RNA PCR values. In receiver operating characteristic analysis CD8+HLA-DR+ percentage had the best combined sensitivity and specificity for discriminating between ILTNPs and non-ILTNPs. CD8+HLA-DR+ percentages of 5% or less predicted ILTNP status with 80% sensitivity and 80% specificity. In multivariate analysis CD8+HLA-DR+ percentage of 5% or less remained a significant predictor of ILTNP status after adjusting for CD3+CD4+ percentage and HIV-1 RNA PCR value (odds ratio, 15.4; 95% CI, 1.9-124.7). CD8+ HLA-DR+ T-lymphocyte percentage of less than 5% at 1 to 2 months of age might be predictive for ILTNP status but should not be used at this time to make treatment-deferral decisions. Immune activation in HIV-infected infants might herald more disease progression. Further study of the use of this subpopulation in early infancy to predict ILTNP status is warranted." @default.
• W2076229213 created "2016-06-24" @default.
• W2076229213 creator A5015640715 @default.
• W2076229213 creator A5016365640 @default.
• W2076229213 creator A5018725181 @default.
• W2076229213 creator A5018848119 @default.
• W2076229213 creator A5021657274 @default.
• W2076229213 creator A5032224704 @default.
• W2076229213 creator A5041793868 @default.
• W2076229213 creator A5067920074 @default.
• W2076229213 creator A5071736558 @default.
• W2076229213 creator A5081550115 @default.
• W2076229213 date "2005-04-01" @default.
• W2076229213 modified "2023-10-02" @default.
• W2076229213 title "Predictors of immunologic long-term nonprogression in HIV-infected children: Implications for initiating therapy" @default.
• W2076229213 cites W1494122660 @default.
• W2076229213 cites W1569669887 @default.
• W2076229213 cites W1591506473 @default.
• W2076229213 cites W1909078944 @default.
• W2076229213 cites W1966624986 @default.
• W2076229213 cites W1968114652 @default.
• W2076229213 cites W1975592062 @default.
• W2076229213 cites W1983226088 @default.
• W2076229213 cites W2015486037 @default.
• W2076229213 cites W2021581373 @default.
• W2076229213 cites W2029777784 @default.
• W2076229213 cites W2034160312 @default.
• W2076229213 cites W2035914865 @default.
• W2076229213 cites W2038243010 @default.
• W2076229213 cites W2045070830 @default.
• W2076229213 cites W2047235790 @default.
• W2076229213 cites W2048458050 @default.
• W2076229213 cites W2054304440 @default.
• W2076229213 cites W2057057794 @default.
• W2076229213 cites W2057586368 @default.
• W2076229213 cites W2058220670 @default.
• W2076229213 cites W2058902571 @default.
• W2076229213 cites W2061765698 @default.
• W2076229213 cites W2068884761 @default.
• W2076229213 cites W2083510193 @default.
• W2076229213 cites W2088287053 @default.
• W2076229213 cites W2089433024 @default.
• W2076229213 cites W2093575763 @default.
• W2076229213 cites W2105397580 @default.
• W2076229213 cites W2122649449 @default.
• W2076229213 cites W2127300645 @default.
• W2076229213 cites W2132081172 @default.
• W2076229213 cites W2144275513 @default.
• W2076229213 cites W2162574459 @default.
• W2076229213 cites W2165031940 @default.
• W2076229213 cites W2166653928 @default.
• W2076229213 cites W2171141994 @default.
• W2076229213 cites W2312499014 @default.
• W2076229213 cites W2318886621 @default.
• W2076229213 cites W2324402215 @default.
• W2076229213 cites W2334332481 @default.
• W2076229213 doi "https://doi.org/10.1016/j.jaci.2004.11.054" @default.
• W2076229213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15806009" @default.
• W2076229213 hasPublicationYear "2005" @default.
• W2076229213 type Work @default.
• W2076229213 sameAs 2076229213 @default.
• W2076229213 citedByCount "46" @default.
• W2076229213 countsByYear W20762292132012 @default.
• W2076229213 countsByYear W20762292132014 @default.
• W2076229213 countsByYear W20762292132015 @default.
• W2076229213 countsByYear W20762292132016 @default.
• W2076229213 countsByYear W20762292132017 @default.
• W2076229213 countsByYear W20762292132018 @default.
• W2076229213 countsByYear W20762292132019 @default.
• W2076229213 countsByYear W20762292132020 @default.
• W2076229213 countsByYear W20762292132021 @default.
• W2076229213 countsByYear W20762292132022 @default.
• W2076229213 crossrefType "journal-article" @default.
• W2076229213 hasAuthorship W2076229213A5015640715 @default.
• W2076229213 hasAuthorship W2076229213A5016365640 @default.
• W2076229213 hasAuthorship W2076229213A5018725181 @default.
• W2076229213 hasAuthorship W2076229213A5018848119 @default.
• W2076229213 hasAuthorship W2076229213A5021657274 @default.
• W2076229213 hasAuthorship W2076229213A5032224704 @default.
• W2076229213 hasAuthorship W2076229213A5041793868 @default.
• W2076229213 hasAuthorship W2076229213A5067920074 @default.
• W2076229213 hasAuthorship W2076229213A5071736558 @default.
• W2076229213 hasAuthorship W2076229213A5081550115 @default.
• W2076229213 hasConcept C126322002 @default.
• W2076229213 hasConcept C142462285 @default.
• W2076229213 hasConcept C144301174 @default.
• W2076229213 hasConcept C147483822 @default.
• W2076229213 hasConcept C156957248 @default.
• W2076229213 hasConcept C167672396 @default.
• W2076229213 hasConcept C188280979 @default.
• W2076229213 hasConcept C203014093 @default.
• W2076229213 hasConcept C2776452011 @default.
• W2076229213 hasConcept C2780648854 @default.
• W2076229213 hasConcept C2780727368 @default.
• W2076229213 hasConcept C3013748606 @default.
• W2076229213 hasConcept C38180746 @default.
• W2076229213 hasConcept C58471807 @default.
• W2076229213 hasConcept C71924100 @default.

• next